Open Interest and Volume Dynamics
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives has increased by 2,194 contracts, marking an 11.27% rise from the previous figure of 19,470 to 21,664. This uptick in OI is accompanied by a robust volume of 24,539 contracts, indicating heightened trader interest and fresh positions being established rather than merely offsetting existing ones.
In monetary terms, the futures segment alone accounts for ₹14,562.03 lakhs, while the options segment’s value is substantially higher at approximately ₹14,843.81 crores, culminating in a total derivatives value of ₹17,882.26 lakhs. This substantial derivatives activity underscores the growing focus on Mankind Pharma within the derivatives market.
Price Performance and Market Positioning
Mankind Pharma’s underlying stock price closed at ₹2,613, just 4.25% shy of its 52-week high of ₹2,716.50. The stock has outperformed its sector by 2.25% on the day, registering a gain of 3.78%, and has been on a two-day winning streak with cumulative returns of 3.92%. Intraday, the stock touched a high of ₹2,608, reflecting strong buying interest.
Technical indicators further reinforce the bullish sentiment, with the stock trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day. This alignment suggests sustained upward momentum and positive investor sentiment.
However, it is noteworthy that delivery volumes have declined by 11.1% compared to the five-day average, with 1.49 lakh shares delivered on 14 July. This dip in investor participation could imply that short-term traders and derivatives players are driving the recent price action rather than long-term holders.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Interpreting the Open Interest Surge
The 11.27% increase in open interest alongside rising volumes typically signals fresh capital entering the market, often reflecting new directional bets. In Mankind Pharma’s case, the concurrent price appreciation and OI growth suggest that traders are positioning for further upside.
Given the stock’s proximity to its 52-week high and its outperformance relative to the broader sector and Sensex (which gained 0.61% on the day), the derivatives market appears to be anticipating continued strength. This is further supported by the futures value of ₹14,562.03 lakhs, indicating significant institutional or large trader participation.
Nevertheless, the decline in delivery volumes hints at a cautious stance among long-term investors, possibly awaiting confirmation of sustained momentum before committing fresh capital. This divergence between derivatives activity and delivery volumes is a key factor for investors to monitor.
Market Capitalisation and Analyst Ratings
Mankind Pharma is classified as a mid-cap company with a market capitalisation of ₹1,06,185 crores. The company’s Mojo Score currently stands at 65.0, reflecting a Hold rating, which was downgraded from a Buy on 1 July 2026. This rating adjustment suggests that while the stock shows promise, there are reservations about its near-term upside potential relative to risk.
Investors should weigh the positive technical signals and derivatives market enthusiasm against the tempered analyst outlook and falling delivery volumes. The Hold rating implies that the stock may consolidate or trade sideways before any significant breakout.
Holding Mankind Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sectoral Context and Broader Market Trends
The Pharmaceuticals & Biotechnology sector has been witnessing mixed trends, with some stocks consolidating while others rally on strong earnings and product pipelines. Mankind Pharma’s recent outperformance by 2.25% relative to its sector peers indicates selective strength, possibly driven by favourable fundamentals or positive news flow.
Its ability to sustain trading above all major moving averages is a technical positive, suggesting that the stock is in a well-established uptrend. However, investors should remain vigilant for any sector-wide headwinds such as regulatory changes or pricing pressures that could impact sentiment.
Investor Takeaways and Outlook
The surge in open interest and volume in Mankind Pharma’s derivatives points to increased speculative interest and potential directional bets favouring further gains. The stock’s proximity to its 52-week high and strong technical positioning support this view.
However, the Hold rating and declining delivery volumes caution investors to monitor for confirmation of sustained buying interest from long-term holders. Those considering exposure should balance the bullish technical signals with the tempered analyst outlook and broader sector dynamics.
In summary, Mankind Pharma currently presents a mixed picture: strong derivatives market activity and price momentum contrasted with cautious fundamental sentiment. Investors with a higher risk appetite may look to capitalise on the momentum, while more conservative participants might await clearer confirmation before increasing exposure.
Summary of Key Metrics:
- Open Interest: 21,664 (up 11.27%)
- Volume: 24,539 contracts
- Futures Value: ₹14,562.03 lakhs
- Options Value: ₹14,843.81 crores
- Stock Price: ₹2,613 (4.25% below 52-week high)
- Day’s Gain: 3.78% (outperforming sector by 2.25%)
- Mojo Score: 65.0 (Hold, downgraded from Buy on 1 July 2026)
- Market Cap: ₹1,06,185 crores (Mid Cap)
Investors should continue to track open interest trends, volume patterns, and delivery volumes closely to gauge the sustainability of the current rally in Mankind Pharma.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
